Fused benzazepines for treatment of Tourette's Syndrome
The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
1. A method of treating Tourette's disorder in a human patient in need thereof, the method comprising:
administering to the patient 0.01 mg/kg to 500 mg/kg per day of ecopipam or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the patient is not older than 18 years.
3. The method of claim 1 , wherein the patient is considered to be free from attention-deficit-hyperactivity disorder, depression, and obsessive-compulsive disorder.
4. A method of treating Tourette's Disorder in a human patient in need thereof, the method comprising
administering to the patient about 0.1 mg to about 500 mg per day of ecopipam or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , comprising administering ecopipam hydrochloride.
6. The method of claim 5 , wherein the ecopipam is formulated for oral delivery.
7. The method of claim 6 , wherein the ecopipam is administered at a daily dose in a range of about 0.01 mg/kg to about 50 mg/kg.
8. The method of claim 7 , wherein ecopipam is administered at a daily dose in a range of about 0.1 mg/kg to about 5 mg/kg.
9. The method of claim 7 , wherein the ecopipam is administered at a dose of 50-100 mg/day.
10. The method of claim 4 , wherein the ecopipam is administered once, twice, or three times daily.
11. The method of claim 1 , further comprising a step of administering a second treatment for treating the tic disorder.
12. The method of claim 11 , wherein the second treatment is a behavioral, surgical, or pharmaceutical therapy.
13. The method of claim 1 , further comprising a step of administering to the subject a therapeutically effective amount of a second composition for the treatment of attention-deficit-hyperactivity disorder, depression, or obsessive-compulsive disorder.
14. The method of claim 1 , wherein the composition is formulated in a unit dosage form.
15. The method of claim 1 , wherein the composition is formulated as a capsule, tablet, pill, powder, or syrup.
16. The method of claim 1 , comprising administering 0.01 mg/kg to 50 mg/kg per day of ecopipam or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 , comprising administering ecopipam hydrochloride.
18. The method of claim 1 , comprising administering 0.1 mg/kg to 5 mg/kg per day of ecopipam or a pharamaceutically acceptable salt thereof.
19. The method of claim 18 , comprising administering ecopipam hydrochloride.
20. A method of treating Tourette's Disorder in a human patient in need thereof and not older than 18 years, comprising administering to the patient once daily oral dosages of ecopipam or a pharmaceutically acceptable salt thereof in a unit dosage form comprising 10 mg to 200 mg ecopipam or a pharmaceutically acceptable salt thereof.
21. A method of treating Tourette's Disorder in a human patient in need thereof and not older than 18 years, comprising administering to the patient once daily oral dosages of ecopipam or a pharmaceutically acceptable salt thereof at a daily dose in a range of about 0.1 mg/kg to about 5 mg/kg.